Cullinan Therapeutics, Inc. (CGEM) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE MAIN STREET
CAMBRIDGE, MA 02142
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments467,067467,292290,466
Cash and cash equivalents98,434156,15259,774
Short-term investments368,633311,140230,692
Prepaid expense13,1247,1806,098
Total current assets:480,191474,472296,564
Noncurrent Assets
Operating lease, right-of-use asset2,5434,130 
Property, plant and equipment9891,17477
Long-term investments and receivables  80,882140,397
Long-term investments  80,882140,397
Other noncurrent assets459459147
Total noncurrent assets:3,99186,645140,621
TOTAL ASSETS:484,182561,117437,185
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26,69716,79511,746
Accounts payable2,4932,6603,169
Accrued liabilities24,20414,1358,577
Other liabilities 9141,955 
Other undisclosed current liabilities5263,748 
Total current liabilities:28,13722,49811,746
Noncurrent Liabilities
Liabilities, other than long-term debt2,1503,59065
Deferred rent credit   65
Operating lease, liability2,1503,590 
Total noncurrent liabilities:2,1503,59065
Total liabilities:30,28726,08811,811
Equity
Equity, attributable to parent453,703535,029424,971
Common stock454
Additional paid in capital654,685585,320584,714
Accumulated other comprehensive loss(129)(2,601)(838)
Accumulated deficit(200,857)(47,695)(158,909)
Equity, attributable to noncontrolling interest 192 403
Total equity:453,895535,029425,374
TOTAL LIABILITIES AND EQUITY:484,182561,117437,185

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues500 18,943
Sublease income500  
Gross profit:500 18,943
Operating expenses(190,649)(132,137)(86,897)
Other undisclosed operating income (loss)(940)276,785 
Operating income (loss):(191,089)144,648(67,954)
Nonoperating income21,8666,668469
Investment income, nonoperating21,6276,611477
Income (loss) from continuing operations before income taxes:(169,223)151,316(67,485)
Income tax expense (benefit) 14,122(42,121) 
Other undisclosed income from continuing operations   
Income (loss) from continuing operations:(155,101)109,195(67,485)
Loss before gain (loss) on sale of properties:(67,485)
Net income (loss):(155,101)109,195(67,485)
Net income attributable to noncontrolling interest1,9392,0191,915
Net income (loss) available to common stockholders, diluted:(153,162)111,214(65,570)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net income (loss):(155,101)109,195(67,485)
Other undisclosed comprehensive income (loss)2,472(1,763)(836)
Comprehensive income (loss):(152,629)107,432(68,321)
Comprehensive income, net of tax, attributable to noncontrolling interest1,9392,0191,915
Comprehensive income (loss), net of tax, attributable to parent:(150,690)109,451(66,406)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: